StockData

Adagene vs Immunome

ADAG and IMNM side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How ADAG and IMNM compare

Adagene grew revenue faster over the last twelve months (7333% versus −63.3% for Immunome).

Adagene keeps more of each dollar of sales as profit, with a net margin of −230% compared with −5594% at Immunome.

Immunome scores higher on the StockData Score (7 against 5 for Adagene), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricADAGIMNM
Size and price
Market cap–$2.0B
Share price$1.48$17.18
Change, 1 year−19.1%0.23%
Change, 5 years−83.0%1.2%
Beta (5Y)0.711.62
Employees128177
StockData Score
Total score57 (better)
Valuation score00
Growth score1 (better)0
Performance score2 (better)1
Health score26 (better)
Dividend score00
Valuation
P/S–486×
P/B–3.3×
FCF yield–−10.5%
Growth
Revenue growth (TTM)7333% (better)−63.3%
Revenue growth, 5Y average61.4%–
Profitability
Operating margin−279% (better)−5948%
Net margin−230% (better)−5594%
FCF margin−204% (better)−5119%
Return on equity−27.7% (better)−50.1%
Financial health
Debt / equity0.06 (better)0.00
Interest coverage−46.3×–
Current ratio5.0221.68 (better)
Altman Z-score–35.70
Piotroski F-score44
Dividends and buybacks
Shareholder yield–0.00%
Ownership
Held by institutions32.5%104%
Held by insiders16.8%6.4%
Insider net buying, 12 months$162K (better)−$25.2M
Short interest, % of float–15.2%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.